Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
The aim of this postmarketing surveillance is to obtain further information about the tolerability and efficacy of Berodual® metered-dose inhaler in the treatment of chronic obstructive respiratory tract disease under conditions of daily practice
Interventions
DRUGBerodual®
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients of either sex over 40 years with the symptoms of a chronic obstructive airways disease * Only patients which have not been treated with Berodual® within the last year should be included
Exclusion criteria
* Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Berodual® metered-dose inhaler
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall severity of the clinical picture rated on a 4- point scale | after 3 and 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of tolerability by investigator on a 4-point scale | after 3 and 6 weeks |
| Assessment of tolerability by patient on a 4-point scale | after 3 and 6 weeks |
| Assessment of efficacy by investigator on a 4-point scale | after 3 and 6 weeks |
| Assessment of efficacy by patient on a 4-point scale | after 3 and 6 weeks |
| Number of patients with adverse drug reactions | up to 6 weeks |
Outcome results
None listed